consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
consenso-venezolano-en-cc3a1ncer-epitelial-de-ovario-2013
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Jorge Sánchez Lan<strong>de</strong>r y col.<br />
241<br />
epithelial ovarian carcinoma: ESMO clinical practice<br />
gui<strong>de</strong>lines for diagnosis, treatm<strong>en</strong>t and follow up. Ann<br />
Oncol. 2010;21(Suppl 5):v23-30.<br />
15. Goff BA. Ovarian cancer scre<strong>en</strong>ing and early <strong>de</strong>tection.<br />
Obstet Gynecol Clin North Am. 2012;39:183-194.<br />
16. Clarke-Pearson DL. Scre<strong>en</strong>ing for ovarian cancer. N<br />
Engl J Med. 2009;361(2):170-177.<br />
17. Collaborative Group on Epi<strong>de</strong>miological Studies<br />
of Ovarian Cancer, Beral V, Doll R, Hermon<br />
C, Peto R, Reeves G. Ovarian cancer and oral<br />
contraceptives: Collaborative reanalysis of data from<br />
45 epi<strong>de</strong>miological studies including 23 257 wom<strong>en</strong><br />
with ovarian cancer and 87 303 controls. Lancet.<br />
2008;371:303-314.<br />
18. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA,<br />
Hankinson SE. Association of oral contraceptive<br />
use, other contraceptive methods, and infertility with<br />
ovarian cancer risk. Am J Epi<strong>de</strong>miol. 2007;166(8):894-<br />
901.<br />
19. Hannaford PC, Selvaraj S, Elliott AM, Angus V,<br />
Ivers<strong>en</strong> L, Lee AJ. Cancer risk among users of oral<br />
contraceptives: Cohort data from the Royal College of<br />
G<strong>en</strong>eral Practitioner's oral contraception study. BMJ.<br />
2007;335;651-658.<br />
20. Lurie G, Thompson P, McDuffie KE, Carney ME,<br />
Terada KY, Goodman MT. Association of estrog<strong>en</strong> and<br />
progestin pot<strong>en</strong>cy of oral contraceptives with ovarian<br />
carcinoma risk. Obstet Gynecol. 2007;109:597-607.<br />
21. Cibula D, Gompel A, Mueck AO, La Vecchia<br />
C, Hannaford PC, Skouby SO, et al. Hormonal<br />
contraception and risk of cancer. Hum Reprod Update.<br />
2010;16(6):631-650.<br />
22. Crane K. Oral contraceptives as ovarian cancer<br />
prev<strong>en</strong>tion. J Natl Cancer Inst. 2011;103(17):1286-<br />
1287.<br />
23. Ness RB, Dodge RC, Edwards RP, Baker JA,<br />
Moysich KB. Contraception methods, beyond oral<br />
contraceptives and tubal ligation, and risk of ovarian<br />
cancer. Ann Epi<strong>de</strong>miol. 2011;21(3):188-196.<br />
24. Bosetti C, Negri E, Trichopoulos D, Franceschi S,<br />
Beral V, Tzonou A, et al. Long-term effects of oral<br />
contraceptives on ovarian cancer risk. Int J Cancer.<br />
2002;102(3):262-265.<br />
25. Schildkraut JM, Calingaert B, Marchbanks PA,<br />
Moorman PG, Rodriguez GC. Impact of progestin<br />
and estrog<strong>en</strong> pot<strong>en</strong>cy in oral contraceptives on ovarian<br />
cancer risk. J Natl Cancer Inst. 2002;94(1):32-38.<br />
26. Narod SA, Risch H, Moslehi R, Dørum A, Neuhaus<strong>en</strong><br />
S, Olsson H, et al. Oral contraceptives and the<br />
risk of hereditary ovarian cancer. N Engl J Med.<br />
1998;339(7):424-428.<br />
27. Bernholtz S, Laitman Y, Kaufman B, Paluch Shimon<br />
S, Friedman E. Cancer risk in Jewish BRCA1 and<br />
BRCA2 mutation carriers: Effects of oral contraceptive<br />
use and par<strong>en</strong>tal origin of mutation. Breast Cancer<br />
Res Treat. 2011;129 (2):557-563.<br />
28. McLaughlin JR, Risch HA, Lubinski J, Moller P,<br />
Ghadirian P, Lynch H, et al. Reproductive risk factors<br />
for ovarian cancer in carriers of BRCA1 or BRCA2<br />
mutations: A case-control study. Lancet Oncol.<br />
2007;8(1):26-34.<br />
29. Ros<strong>en</strong> B, Kwon J, Fung Kee Fung M, Gagliardi A,<br />
Chambers A, et al. Systematic review of managem<strong>en</strong>t<br />
options for wom<strong>en</strong> with a hereditary predisposition to<br />
ovarian cancer. Gynecol Oncol. 2004;93(2):280-286.<br />
30. Domchek SM, Friebel TM, Singer CF, Evans DG,<br />
Lynch HT, Isaacs C, et al. Association of risk-reducing<br />
surgery in BRCA1 or BRCA2: Mutation carriers with<br />
cancer risk and mortality. JAMA. 2010;304(9):967-<br />
975.<br />
31. Rebbeck TR, Kauff ND, Domchek SM. Metaanalysis<br />
of risk reduction estimates associated with<br />
risk-reducing salpingo-oophorectomy in BRCA1<br />
or BRCA2 Mutation carriers. J Natl Cancer Inst.<br />
2009;101(2):80-87.<br />
32. Rebbeck TR, Lynch HT, Neuhaus<strong>en</strong> SL, Narod<br />
SA, Van't Veer L, Garber JE, et al. Prophylactic<br />
oophorectomy in carriers of BRCA1 or BRCA2<br />
mutations. N Engl J Med. 2002;346:1616-1622.<br />
33. Kauff ND, Satagopan J. Risk-reducing salpingooophorectomy<br />
in wom<strong>en</strong> with a BRCA1 or BRCA2<br />
mutation. N Engl J Med. 2002;346(21):1609-1615.<br />
34. Kauff ND, Domchek SM, Friebel TM, Robson ME,<br />
Lee J, Garber JE, et al. Risk-reducing salpingooophorectomy<br />
for the prev<strong>en</strong>tion of BRCA1- and<br />
BRCA2-associated breast and gynecologic cancer:<br />
A multic<strong>en</strong>ter, prospective study. J Clin Oncol.<br />
2008;26(8):1331-1337.<br />
35. Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff<br />
E, Eeles R, et al. Occult ovarian cancers id<strong>en</strong>tified at<br />
risk-reducing salpingo-oophorectomy in a prospective<br />
cohort of BRCA1/2 mutation in a prospective cohort<br />
of BRCA1/2 mutation carriers. Breast Cancer Res<br />
Treat. 2010;124(1):195-203.<br />
36. [No authors List] NCCN. G<strong>en</strong>etic/familial high risk<br />
assessm<strong>en</strong>t breast and ovarian. NCCN gui<strong>de</strong>lines<br />
version 1. 2012. Panel members. Disponible <strong>en</strong>:<br />
URL:www.nccn.org.<br />
Rev V<strong>en</strong>ez Oncol